Published in Law and Health Weekly, April 30th, 2005
CCR5 mAb is a fully human monoclonal antibody that specifically recognizes and binds the chemokine receptor CCR5. The CCR5 receptor is known to be a key facilitator of infection with human immunodeficiency virus (HIV-1). The phase I trial of CCR5 mAb is a randomized, placebo-controlled, dose-escalation, multicenter study in HIV-1 patients who are infected with HIV-1 and are not receiving concurrent antiretroviral therapy. The...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.